Immunai, an AI biotech firm specializing in mapping the human immune system, has expanded its collaboration with AstraZeneca in a deal potentially worth up to $37.5 million over the next two years. This agreement extends their previous partnerships focused on oncology clinical development and builds on a 2024 deal that applied Immunai’s AMICA-OS platform across AstraZeneca’s oncology programs. The AMICA-OS system utilizes a comprehensive clinical immunology database and advanced AI to enhance drug development insights, including biomarker discovery and patient stratification. AstraZeneca’s chief of AI for science innovation, Jorge Reis-Filho, emphasized the company’s commitment to investing in innovative AI solutions to improve patient outcomes, reflecting their belief in the transformative power of AI in clinical development.
Immunai: Immunai is a New York-headquartered, Israeli-founded AI biotech company that uses single-cell genomics and machine learning to map and decode the human immune system for next-generation therapeutics. Its AMICA-OS platform integrates immune data with AI models to generate clinically relevant insights. The company recently expanded its multi-year collaboration with AstraZeneca, enabling continued application of the platform in oncology clinical development through 2027.
AMICA-OS: AMICA-OS is Immunai’s AI operating system combining a large-scale clinical immunology database at single-cell resolution with advanced AI models of the immune system. The platform supports oncology drug development via biomarker discovery, patient stratification, mechanism-of-action analysis, and dose optimization. AstraZeneca will use it under the new agreement extending through 2027.
AstraZeneca: AstraZeneca is a global biopharmaceutical company advancing oncology and other therapies through integration of AI and advanced technologies. It invests in frontier AI solutions to enhance clinical development decisions and biomarker discovery. In this expanded deal, AstraZeneca continues leveraging Immunai’s platform across its oncology programs.
Noam Solomon: Noam Solomon is the CEO and co-founder of Immunai, driving the application of AI and single-cell data to immune system decoding for therapeutics. He emphasized the expanded AstraZeneca collaboration as validation of the platform’s mechanistic and clinical relevance.
Jorge Reis-Filho: Jorge Reis-Filho is AstraZeneca’s Chief of AI for Science Innovation, bringing expertise in molecular pathology, bioinformatics, functional genomics, and AI. He noted the collaboration expansion reflects confidence in AI’s potential to improve oncology patient outcomes through novel biomarkers.
Platform Validation: Immunai’s technology has drawn partnerships with major pharma firms seeking immune insights for drug development.
Collaboration History: The expansion builds on prior agreements, including a 2024 oncology clinical program deal and a 2025 extension into inflammatory bowel disease.
AI in Clinical Development: AstraZeneca continuously invests in frontier AI models to derive mechanistically informed biomarkers for clinical decisions.